Clinical Characteristics and Drug Resistance Analysis of 90 Cases of Children with Salmonella Enteritis

OBJECTIVE: To summarize the clinical characteristics and drug sensitivity analysis of children with Salmonella enteritis in our hospital, explore the characteristics and drug resistance of Salmonella infection, and guide the rational clinical use of drugs. METHODS: The clinical data of 90 pediatric Salmonella enteritis patients treated in our hospital from January 2015 to January 2020 were selected as the observation group of this retrospective study, and 90 patients with non-Salmonella enteritis were selected at the same time as a control group. Discuss the clinical characteristics of Salmonella, drug sensitivity analysis, infection characteristics, and drug resistance and guide the rational clinical use of drugs. RESULTS: The susceptibility rates of 15 antibiotics from high to low were imipenem and meropenem, piperacillin, cefoperazone, compound trimethoprim, chloramphenicol, and ceftazidime. Salmonella strains were both resistant to imipenem and meropenem. Salmonella is sensitive and has a low rate of resistance to quinolones (ciprofloxacin) and a high rate of resistance to cephalosporins (ceftriaxone, cefotaxime, ceftazime, and cefpiramide), both reached more than 28%. Salmonella has the highest resistance to penicillin and erythromycin, both at 85.00% and above. Among 90 children with Salmonella enteritidis food poisoning, 32 were hospitalized, 21 cases were hospitalized less than 7 days, and 11 cases were 7-14 days. The longest hospital stay was 12 days, the shortest was 1 day, and the average was 6.1 days. Seven people stayed for observation and 51 people were discharged after treatment. All the children recovered without death. CONCLUSION: In clinical practice, antibiotics should be used rationally based on drug susceptibility results. In the case of poor efficacy of cephalosporins, amoxicillin and potassium clavulanate, piperacillin, tazobactam, or imipenem, cephalosporin antibiotics can be considered the first choice for clinical empiric medication.